Key Highlights

● CRBU shares fell 22.06% to $0.48 in Thursday’s October 8 session after a pipeline restructuring.

● Caribou’s board approved a plan to discontinue development of two lead allogeneic CAR T programs.

● The plan also includes a substantial workforce reduction while the company explores its strategic alternatives.

Caribou Biosciences (NASDAQ:CRBU) was among Thursday’s notable decliners, closing at $0.48, down 22.06% on the day. That price sits far below the range in which this CRISPR-focused cell-therapy company has historically traded. For most of its life as a public company Caribou changed hands at several dollars and higher, and as recently as the summer of 2026 the shares were quoted in the range of roughly a dollar and a half.

A Slide Toward the 52-Week Low

According to market data, the stock sits near its 52-week low, which is in the mid-forty-cent area, having fallen from above a dollar to around that level within roughly a week. The decline traces to a confirmed corporate event.

The Restructuring and Pipeline Discontinuation

Earlier in October, Caribou disclosed a sweeping restructuring. In a securities filing dated around October 6, the company said its board had approved a plan to discontinue the Clinical Trials and development of its two lead allogeneic CAR-T programs, along with a substantial reduction of its workforce, while it explores strategic alternatives. The filing described restructuring costs estimated in the mid-teens of millions of dollars, disclosed that most affected employees were expected to depart in the fourth quarter, named a Financial Advisor engaged to assist with the strategic review, and noted a planned departure of the chief financial officer upon any binding strategic transaction. The company pointed to a difficult financing environment for these therapies as part of the rationale.

For a clinical-stage biotech whose value rested on the promise of that pipeline, abandoning its lead programs is about as fundamental a reset as a company can announce, and it strips away much of the thesis that had supported the shares.

Fallout Rather Than a New Catalyst

Thursday’s decline is best understood as a continuation of the fallout from that disclosure rather than the product of a separate catalyst on the day itself. When a stock is digesting news of this magnitude, selling pressure often persists across multiple sessions as holders exit, as the shares drift toward whatever residual value the market assigns to a company in restructuring and strategic review, and as the stock takes on the trading characteristics of a distressed, low-priced security prone to large daily swings.

A Risk-Off Tape for Capital-Dependent Biotech

The broader market gave no relief. Thursday was a risk-off session led by technology weakness, with the Nasdaq Composite down about 1.25% to roughly 27,193 amid a semiconductor and AI-infrastructure selloff. Clinical-stage biotech, which depends heavily on access to capital, is particularly sensitive to a risk-averse tape and to elevated Treasury yields, with the 10-year hovering near multidecade highs around 5.3%. A company that has just cited a difficult financing environment as a reason to shelve its pipeline is precisely the kind of name that struggles most when investors retreat from risk.

A Sub-Fifty-Cent Price Tied to a Real Reset

The price, while far below Caribou’s historical range, reflects a genuine collapse tied to the early-October restructuring and pipeline discontinuation, and Thursday’s further decline represents continued fallout from that event in a weak market. With the lead programs discontinued and a financial advisor engaged for the strategic review, much of the pipeline thesis that supported the shares has been stripped away.